Carisma Therapeutics (CARM) Competitors $0.39 -0.02 (-5.39%) Closing price 04:00 PM EasternExtended Trading$0.39 0.00 (-0.41%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CARM vs. EVGN, MURA, XCUR, JATT, RNXT, SCYX, HYPD, MDCX, THAR, and DYAIShould you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Evogene (EVGN), Mural Oncology (MURA), Exicure (XCUR), JATT Acquisition (JATT), RenovoRx (RNXT), SCYNEXIS (SCYX), Hyperion DeFi (HYPD), Medicus Pharma (MDCX), Tharimmune (THAR), and Dyadic International (DYAI). These companies are all part of the "medical" sector. Carisma Therapeutics vs. Its Competitors Evogene Mural Oncology Exicure JATT Acquisition RenovoRx SCYNEXIS Hyperion DeFi Medicus Pharma Tharimmune Dyadic International Evogene (NASDAQ:EVGN) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk. Do analysts rate EVGN or CARM? Evogene currently has a consensus price target of $3.50, suggesting a potential upside of 172.80%. Carisma Therapeutics has a consensus price target of $1.93, suggesting a potential upside of 391.57%. Given Carisma Therapeutics' higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Carisma Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71 Is EVGN or CARM more profitable? Evogene has a net margin of -211.61% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Evogene-211.61% -109.96% -38.47% Carisma Therapeutics -254.28%N/A -192.17% Does the media prefer EVGN or CARM? In the previous week, Evogene had 1 more articles in the media than Carisma Therapeutics. MarketBeat recorded 1 mentions for Evogene and 0 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score. Company Overall Sentiment Evogene Neutral Carisma Therapeutics Neutral Which has stronger earnings and valuation, EVGN or CARM? Evogene has higher earnings, but lower revenue than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvogene$8.51M0.81-$16.49M-$2.25-0.57Carisma Therapeutics$10.77M1.52-$60.48M-$1.56-0.25 Do institutionals and insiders have more ownership in EVGN or CARM? 10.4% of Evogene shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, EVGN or CARM? Evogene has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. SummaryCarisma Therapeutics beats Evogene on 9 of the 15 factors compared between the two stocks. Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARM vs. The Competition Export to ExcelMetricCarisma TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.36M$2.52B$5.76B$10.03BDividend YieldN/A49.23%5.28%4.52%P/E Ratio-0.2523.3575.4326.15Price / Sales1.52500.40515.98171.98Price / CashN/A167.9837.2059.76Price / Book-0.585.2711.536.20Net Income-$60.48M$32.95M$3.28B$270.56M7 Day Performance5.87%1.28%0.42%2.70%1 Month Performance45.04%30.53%10.81%8.77%1 Year Performance-60.40%1.94%61.62%27.50% Carisma Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARMCarisma Therapeutics2.0529 of 5 stars$0.39-5.4%$1.93+391.6%-59.0%$16.36M$10.77M-0.2520Short Interest ↑EVGNEvogene2.2375 of 5 stars$1.25-3.3%$3.50+180.0%-58.4%$6.71M$8.51M-0.56140MURAMural Oncology3.2849 of 5 stars$2.06-0.5%$12.00+482.5%-31.4%$35.69MN/A-0.24119XCURExicure1.6408 of 5 stars$5.61-0.1%N/A+139.9%$35.44M$500K-1.4450Gap DownJATTJATT AcquisitionN/A$2.04-3.8%N/A-39.0%$35.19MN/A0.003High Trading VolumeRNXTRenovoRx1.8965 of 5 stars$0.96+1.3%$7.50+681.3%+7.4%$35.18M$40K-2.536Short Interest ↑SCYXSCYNEXIS0.6605 of 5 stars$0.83-2.2%N/A-28.5%$34.86M$3.75M-2.0860HYPDHyperion DeFi0.2491 of 5 stars$6.10-8.0%$2.00-67.2%-80.6%$34.74M$60K-0.1040News CoverageGap UpMDCXMedicus Pharma1.648 of 5 stars$1.94-3.0%$23.50+1,111.3%N/A$34.56MN/A-1.45N/AGap UpTHARTharimmune2.9784 of 5 stars$5.95-1.7%$17.00+185.7%-5.1%$33.86MN/A-0.982Gap UpDYAIDyadic International3.0945 of 5 stars$0.92+1.5%$6.00+551.3%-20.9%$33.34M$3.49M-4.857Analyst ForecastShort Interest ↓ Related Companies and Tools Related Companies Evogene Alternatives Mural Oncology Alternatives Exicure Alternatives JATT Acquisition Alternatives RenovoRx Alternatives SCYNEXIS Alternatives Hyperion DeFi Alternatives Medicus Pharma Alternatives Tharimmune Alternatives Dyadic International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CARM) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersThis stock just surpassed PalantirThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredOne tiny company just cracked Google’s $19B problemTucked away outside San Antonio sits a facility most Americans don’t know exists. It’s not mining gold or o...True Market Insiders | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredWorld War 3? Everything Just Changed — and One Tiny Company Is at the Center of It.Trump immediately activated a $5.3 TRILLION AI missile shield — code-named Golden Dome — to stop drone swarms ...Angel Publishing | SponsoredLitecoin’s Creator Backs the World’s First TreasuryBitcoin's corporate adoption story has been written. Litecoin's is just beginning.The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CARM Stock Alerts